Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing
Open Access
Abstract
Colorectal cancer (CRC) is the third most common cancer in the world. Despite improvement in standardized screening methods and the development of promising therapies, the 5-year survival rates are as low as 10% in the metastatic setting. The increasing life expectancy of the general population, higher rates of obesity, poor diet, and comorbidities contribute to the increasing trends in incidence. Drug repurposing offers an affordable solution to achieve new indications for previously approved drugs that could play a protagonist or adjuvant role in the treatment of CRC with the advantage of treating underlying comorbidities and decreasing chemotherapy toxicity. This review elaborates on the current data that supports drug repurposing as a feasible option for patients with CRC with a focus on the evidence and mechanism of action promising repurposed candidates that are widely used, including but not limited to anti-malarial, anti-helminthic, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic, and anti-diabetic agents.Keywords
This publication has 144 references indexed in Scilit:
- Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerJournal of Cancer Research and Clinical Oncology, 2013
- Mechanistic and Pharmacological Issues of Aspirin as an Anticancer AgentPharmaceuticals, 2012
- Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic Carcinogen Mouse ModelPLOS ONE, 2012
- In Vitro and Ex Vivo Inhibition of Human Telomerase by Anti-HIV Nucleoside Reverse Transcriptase Inhibitors (NRTIs) but Not by Non-NRTIsPLOS ONE, 2012
- The role of aspirin in cancer preventionNature Reviews Clinical Oncology, 2012
- Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC MutationsCancer Research, 2011
- Drug repurposing from an academic perspectiveDrug Discovery Today: Therapeutic Strategies, 2011
- Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , PI3K and Akt1Carcinogenesis, 2010
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2New England Journal of Medicine, 2007
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006